NEWS
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has strengthened its co-development agreement with Orano Med for 212Pb-based Radio-DARPin Therapeutics. The revised agreement now includes four Radio-DARPin programs, with each company holding commercialization rights to two programs. Molecular Partners retains rights to the first program, MP0712 targeting DLL3, and gains rights to the second nominated Radio-DARPin Candidate.
The companies plan to initiate first-in-human studies for MP0712 in 2025, pending regulatory clearance. Molecular Partners expects no immediate impact on its 2024 financial forecast and maintains its funding guidance into 2027. The company's estimated cash and cash equivalents as of September 30, 2024, are approximately CHF 140 million(unaudited).
The companies plan to initiate first-in-human studies for MP0712 in 2025, pending regulatory clearance. Molecular Partners expects no immediate impact on its 2024 financial forecast and maintains its funding guidance into 2027. The company's estimated cash and cash equivalents as of September 30, 2024, are approximately CHF 140 million(unaudited).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment